# EDGAR Filing Document

**Accession Number:** 0001314966
**File Stem:** 0001410368-26-054541
**Filing Date:** 2026-5
**Character Count:** 84630
**Document Hash:** 1d46abcc312fff3af92c20b7560f2ff7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-054541.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001410368-26-054541

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**PERIOD START**: 20261231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock Health Sciences Trust
- **CENTRAL INDEX KEY:** 0001314966

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-21702
- **FILM NUMBER:** 261030955

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** (888) 825-2257

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

## Nport-Ex

March 31, 2026

2026 Quarterly Report <br>&nbsp;&nbsp;&nbsp;&nbsp;(Unaudited)<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**BlackRock Health Sciences Trust (BME)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Not FDIC Insured • May Lose Value • No Bank Guarantee**<br>

------

Schedule of Investments (unaudited)

March 31, 2026

**BlackRock Health Sciences Trust (BME)** 

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | <br>*Shares*<br>| *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 31.2%** | **Biotechnology — 31.2%** |  |
| 4D Molecular Therapeutics, Inc.<sup>(a)</sup> | 11491 | &nbsp;&nbsp; $106981 |
| AbbVie, Inc.<sup>(b)</sup> | 100720 | &nbsp;&nbsp; 21905593 |
| Agios Pharmaceuticals, Inc.<sup>(a)</sup> | 30245 | &nbsp;&nbsp; 1023188 |
| Aktis Oncology, Inc.<sup>(a)</sup> | 23229 | &nbsp;&nbsp; 415567 |
| Allogene Therapeutics, Inc.<sup>(a)</sup> | 105465 | &nbsp;&nbsp; 257335 |
| Alnylam Pharmaceuticals, Inc.<sup>(a)</sup> | 8378 | &nbsp;&nbsp; 2772029 |
| Amgen, Inc.<sup>(b)</sup> | 51861 | &nbsp;&nbsp; 18247293 |
| Apogee Therapeutics, Inc.<sup>(a)</sup> | 17780 | &nbsp;&nbsp; 1496543 |
| Arcellx, Inc.<sup>(a)</sup> | 8208 | &nbsp;&nbsp; 942442 |
| Arcus Biosciences, Inc.<sup>(a)</sup> | 39654 | &nbsp;&nbsp; 856526 |
| Argenx SE, ADR<sup>(a)</sup> | 10637 | &nbsp;&nbsp; 7767669 |
| Beam Therapeutics, Inc.<sup>(a)</sup> | 14611 | &nbsp;&nbsp; 348180 |
| Bicara Therapeutics, Inc.<sup>(a)</sup> | 14144 | &nbsp;&nbsp; 281324 |
| Biogen, Inc.<sup>(a)</sup> | 31869 | &nbsp;&nbsp; 5842544 |
| Biohaven Ltd.<sup>(a)</sup> | 30469 | &nbsp;&nbsp; 257768 |
| BioMarin Pharmaceutical, Inc.<sup>(a)</sup> | 29577 | &nbsp;&nbsp; 1670805 |
| BioNTech SE, ADR<sup>(a)</sup> | 3695 | &nbsp;&nbsp; 328412 |
| &nbsp;&nbsp;&nbsp; Bridgebio Oncology Therapeutics, Inc., (Acquired <br> 08/08/25, Cost: $167,000)<sup>(a)(c)</sup><br>| 15582 | &nbsp;&nbsp; 139459 |
| BridgeBio Oncology Therapeutics, Inc.<sup>(a)</sup> | 60030 | &nbsp;&nbsp; 537268 |
| Bridgebio Pharma, Inc.<sup>(a)</sup> | 18055 | &nbsp;&nbsp; 1340764 |
| Bright Minds Biosciences, Inc.<sup>(a)</sup> | 8368 | &nbsp;&nbsp; 610613 |
| CG oncology, Inc.<sup>(a)</sup> | 5095 | &nbsp;&nbsp; 344830 |
| Cogent Biosciences, Inc.<sup>(a)</sup> | 124642 | &nbsp;&nbsp; 4797471 |
| Corvus Pharmaceuticals, Inc.<sup>(a)</sup> | 9689 | &nbsp;&nbsp; 141750 |
| Cytokinetics, Inc.<sup>(a)</sup> | 16255 | &nbsp;&nbsp; 1071367 |
| Denali Therapeutics, Inc.<sup>(a)</sup> | 22218 | &nbsp;&nbsp; 426586 |
| Dianthus Therapeutics, Inc.<sup>(a)</sup> | 16460 | &nbsp;&nbsp; 1381323 |
| Dyne Therapeutics, Inc.<sup>(a)</sup> | 23908 | &nbsp;&nbsp; 433452 |
| Eikon Therapeutics, Inc.<sup>(a)(d)</sup> | 63218 | &nbsp;&nbsp; 668846 |
| Enanta Pharmaceuticals, Inc.<sup>(a)</sup> | 42512 | &nbsp;&nbsp; 536926 |
| Erasca, Inc.<sup>(a)</sup> | 62282 | &nbsp;&nbsp; 1007723 |
| Exelixis, Inc.<sup>(a)</sup> | 19863 | &nbsp;&nbsp; 851924 |
| Gilead Sciences, Inc. | 150487 | &nbsp;&nbsp; 20973373 |
| Gossamer Bio, Inc.<sup>(a)(d)</sup> | 31955 | &nbsp;&nbsp; 10497 |
| Immunocore Holdings PLC, ADR<sup>(a)</sup> | 16565 | &nbsp;&nbsp; 499435 |
| Immunome, Inc.<sup>(a)</sup> | 25340 | &nbsp;&nbsp; 554186 |
| Incyte Corp.<sup>(a)</sup> | 34568 | &nbsp;&nbsp; 3253540 |
| Insmed, Inc.<sup>(a)(d)</sup> | 34614 | &nbsp;&nbsp; 5660081 |
| Intellia Therapeutics, Inc.<sup>(a)(d)</sup> | 45705 | &nbsp;&nbsp; 585938 |
| Ionis Pharmaceuticals, Inc.<sup>(a)</sup> | 14983 | &nbsp;&nbsp; 1125073 |
| &nbsp;&nbsp;&nbsp; Kailera Therapeutics, Inc., Series B, (Acquired 10/31/25, <br> Cost: $504,000)<sup>(a)(c)(e)</sup><br>| 36000 | &nbsp;&nbsp; 504000 |
| KalVista Pharmaceuticals, Inc.<sup>(a)</sup> | 18705 | &nbsp;&nbsp; 376532 |
| Kodiak Sciences, Inc.<sup>(a)</sup> | 11389 | &nbsp;&nbsp; 434149 |
| Kymera Therapeutics, Inc.<sup>(a)</sup> | 4712 | &nbsp;&nbsp; 392462 |
| Moderna, Inc.<sup>(a)</sup> | 48852 | &nbsp;&nbsp; 2481682 |
| Monte Rosa Therapeutics, Inc.<sup>(a)</sup> | 27954 | &nbsp;&nbsp; 459843 |
| MoonLake Immunotherapeutics<sup>(a)</sup> | 14299 | &nbsp;&nbsp; 266533 |
| Natera, Inc.<sup>(a)</sup> | 11821 | &nbsp;&nbsp; 2364082 |
| Neurocrine Biosciences, Inc.<sup>(a)</sup> | 6793 | &nbsp;&nbsp; 894910 |
| Nuvalent, Inc., Class A<sup>(a)(d)</sup> | 28618 | &nbsp;&nbsp; 2931914 |
| Oruka Therapeutics, Inc.<sup>(a)</sup> | 15986 | &nbsp;&nbsp; 784113 |
| Palvella Therapeutics, Inc.<sup>(a)</sup> | 4480 | &nbsp;&nbsp; 558432 |
| Protagonist Therapeutics, Inc.<sup>(a)</sup> | 32058 | &nbsp;&nbsp; 3378913 |
| PTC Therapeutics, Inc.<sup>(a)</sup> | 4329 | &nbsp;&nbsp; 294935 |
| Regeneron Pharmaceuticals, Inc. | 7712 | &nbsp;&nbsp; 5958600 |
| REGENXBIO, Inc.<sup>(a)</sup> | 18415 | &nbsp;&nbsp; 154318 |
| Revolution Medicines, Inc.<sup>(a)</sup> | 26560 | &nbsp;&nbsp; 2582960 |
| Rhythm Pharmaceuticals, Inc.<sup>(a)</sup> | 46799 | &nbsp;&nbsp; 4070109 |

---

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** |  |
| Roivant Sciences Ltd.<sup>(a)</sup> | 41221 | &nbsp;&nbsp; $1141822 |
| Scholar Rock Holding Corp.<sup>(a)</sup> | 19764 | &nbsp;&nbsp; 971598 |
| Stoke Therapeutics, Inc.<sup>(a)</sup> | 41095 | &nbsp;&nbsp; 1338053 |
| Summit Therapeutics, Inc.<sup>(a)(d)</sup> | 80150 | &nbsp;&nbsp; 1519644 |
| Syndax Pharmaceuticals, Inc.<sup>(a)</sup> | 5165 | &nbsp;&nbsp; 120654 |
| TScan Therapeutics, Inc.<sup>(a)</sup> | 48273 | &nbsp;&nbsp; 48756 |
| United Therapeutics Corp.<sup>(a)</sup> | 4903 | &nbsp;&nbsp; 2907381 |
| Upstream Bio, Inc.<sup>(a)</sup> | 30052 | &nbsp;&nbsp; 270468 |
| Vaxcyte, Inc.<sup>(a)</sup> | 7541 | &nbsp;&nbsp; 438207 |
| Vertex Pharmaceuticals, Inc.<sup>(a)</sup> | 31983 | &nbsp;&nbsp; 14281689 |
| Viking Therapeutics, Inc.<sup>(a)</sup> | 36985 | &nbsp;&nbsp; 1203492 |
| Viridian Therapeutics, Inc.<sup>(a)</sup> | 45005 | &nbsp;&nbsp; 880298 |
| Vor BioPharma, Inc.<sup>(a)</sup> | 10020 | &nbsp;&nbsp; 178757 |
| Voyager Therapeutics, Inc.<sup>(a)</sup> | 31420 | &nbsp;&nbsp; 121281 |
| Zealand Pharma A/S<sup>(a)</sup> | 7187 | &nbsp;&nbsp; 334699 |
|  |  | &nbsp;&nbsp; 166117910 |
| **Health Care Equipment & Supplies — 15.0%** | **Health Care Equipment & Supplies — 15.0%** |  |
| Abbott Laboratories<sup>(b)</sup> | 119561 | &nbsp;&nbsp; 12275328 |
| Alcon AG | 5751 | &nbsp;&nbsp; 433338 |
| Boston Scientific Corp.<sup>(a)(b)</sup> | 131399 | &nbsp;&nbsp; 8245287 |
| Cooper Cos., Inc.<sup>(a)</sup> | 26747 | &nbsp;&nbsp; 1912411 |
| Dexcom, Inc.<sup>(a)</sup> | 57910 | &nbsp;&nbsp; 3636748 |
| Edwards Lifesciences Corp.<sup>(a)</sup> | 149905 | &nbsp;&nbsp; 12004392 |
| &nbsp;&nbsp;&nbsp; EXO Imaging, Inc., (Acquired 06/24/21, Cost: <br> $595,999)<sup>(a)(c)(e)</sup><br>| 1017 | &nbsp;&nbsp; 376 |
| Glaukos Corp.<sup>(a)</sup> | 7625 | &nbsp;&nbsp; 820908 |
| Hologic, Inc.<sup>(a)</sup> | 12193 | &nbsp;&nbsp; 921669 |
| IDEXX Laboratories, Inc.<sup>(a)</sup> | 6712 | &nbsp;&nbsp; 3771406 |
| Intuitive Surgical, Inc.<sup>(a)</sup> | 27505 | &nbsp;&nbsp; 12679530 |
| Medline, Inc., Class A<sup>(a)</sup> | 70645 | &nbsp;&nbsp; 3143703 |
| Medtronic PLC | 77050 | &nbsp;&nbsp; 6676382 |
| Novocure Ltd.<sup>(a)</sup> | 49947 | &nbsp;&nbsp; 544422 |
| Nucleix Ltd., (Acquired 04/10/24, Cost: $200,000)<sup>(a)(c)(e)</sup> | 200 | &nbsp;&nbsp; 158504 |
| Nyxoah SA<sup>(a)(d)</sup> | 29659 | &nbsp;&nbsp; 86604 |
| Orchestra BioMed Holdings, Inc.<sup>(a)</sup> | 17635 | &nbsp;&nbsp; 74949 |
| Penumbra, Inc.<sup>(a)</sup> | 11606 | &nbsp;&nbsp; 3811062 |
| STERIS PLC | 5880 | &nbsp;&nbsp; 1300244 |
| Stryker Corp. | 23649 | &nbsp;&nbsp; 7770825 |
|  |  | &nbsp;&nbsp; 80268088 |
| **Health Care Providers & Services — 7.6%** | **Health Care Providers & Services — 7.6%** |  |
| Cencora, Inc., Class A | 15981 | &nbsp;&nbsp; 5020271 |
| CVS Health Corp. | 31771 | &nbsp;&nbsp; 2281793 |
| Elevance Health, Inc. | 7713 | &nbsp;&nbsp; 2257981 |
| Guardant Health, Inc.<sup>(a)</sup> | 39876 | &nbsp;&nbsp; 3683346 |
| HCA Healthcare, Inc. | 10937 | &nbsp;&nbsp; 5175826 |
| Humana, Inc. | 6765 | &nbsp;&nbsp; 1172983 |
| McKesson Corp. | 2993 | &nbsp;&nbsp; 2590022 |
| Quest Diagnostics, Inc. | 7463 | &nbsp;&nbsp; 1462599 |
| RadNet, Inc.<sup>(a)(d)</sup> | 9485 | &nbsp;&nbsp; 530117 |
| UnitedHealth Group, Inc.<sup>(b)</sup> | 59867 | &nbsp;&nbsp; 16199412 |
|  |  | &nbsp;&nbsp; 40374350 |
| **Health Care Technology — 0.3%** | **Health Care Technology — 0.3%** |  |
| Veeva Systems, Inc., Class A<sup>(a)</sup> | 8702 | &nbsp;&nbsp; 1528593 |
| **Life Sciences Tools & Services — 6.9%** | **Life Sciences Tools & Services — 6.9%** |  |
| Agilent Technologies, Inc. | 23884 | &nbsp;&nbsp; 2722298 |
| Bio-Techne Corp. | 17090 | &nbsp;&nbsp; 893123 |
| Bruker Corp. | 43307 | &nbsp;&nbsp; 1564249 |
| Charles River Laboratories International, Inc.<sup>(a)</sup> | 4936 | &nbsp;&nbsp; 851460 |
| Danaher Corp. | 54385 | &nbsp;&nbsp; 10311396 |
| Illumina, Inc.<sup>(a)</sup> | 13293 | &nbsp;&nbsp; 1638495 |

---

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Trust (BME)** 

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Life Sciences Tools & Services (continued)** | **Life Sciences Tools & Services (continued)** |  |
| IQVIA Holdings, Inc.<sup>(a)</sup> | 12502 | &nbsp;&nbsp; $2132091 |
| Mettler-Toledo International, Inc.<sup>(a)</sup> | 395 | &nbsp;&nbsp; 498174 |
| Thermo Fisher Scientific, Inc. | 23314 | &nbsp;&nbsp; 11459531 |
| Waters Corp.<sup>(a)</sup> | 10927 | &nbsp;&nbsp; 3254061 |
| West Pharmaceutical Services, Inc. | 5328 | &nbsp;&nbsp; 1335410 |
|  |  | &nbsp;&nbsp; 36660288 |
| **Pharmaceuticals — 36.2%** | **Pharmaceuticals — 36.2%** |  |
| Alumis, Inc.<sup>(a)</sup> | 25795 | &nbsp;&nbsp; 568264 |
| AstraZeneca PLC | 33842 | &nbsp;&nbsp; 6617463 |
| Bristol-Myers Squibb Co. | 96259 | &nbsp;&nbsp; 5838108 |
| Daiichi Sankyo Co. Ltd. | 60800 | &nbsp;&nbsp; 1087752 |
| Edgewise Therapeutics, Inc.<sup>(a)(d)</sup> | 22279 | &nbsp;&nbsp; 701788 |
| Elanco Animal Health, Inc.<sup>(a)</sup> | 41073 | &nbsp;&nbsp; 982877 |
| Eli Lilly & Co.<sup>(b)</sup> | 59379 | &nbsp;&nbsp; 54615023 |
| EyePoint, Inc.<sup>(a)</sup> | 16320 | &nbsp;&nbsp; 210365 |
| Galderma Group AG | 16599 | &nbsp;&nbsp; 3262263 |
| Johnson & Johnson<sup>(b)</sup> | 234293 | &nbsp;&nbsp; 57270581 |
| LB Pharmaceuticals, Inc.<sup>(a)(d)</sup> | 48308 | &nbsp;&nbsp; 1191275 |
| Maze Therapeutics, Inc.<sup>(a)(d)</sup> | 15965 | &nbsp;&nbsp; 476555 |
| MBX Biosciences, Inc.<sup>(a)</sup> | 28457 | &nbsp;&nbsp; 849441 |
| Merck & Co., Inc.<sup>(b)</sup> | 237354 | &nbsp;&nbsp; 28551313 |
| Novartis AG, ADR | 21810 | &nbsp;&nbsp; 3331477 |
| Ocular Therapeutix, Inc.<sup>(a)</sup> | 22645 | &nbsp;&nbsp; 191803 |
| Pfizer, Inc. | 522250 | &nbsp;&nbsp; 14664780 |
| Terns Pharmaceuticals, Inc.<sup>(a)</sup> | 32290 | &nbsp;&nbsp; 1702329 |
| Teva Pharmaceutical Industries Ltd., ADR<sup>(a)</sup> | 304107 | &nbsp;&nbsp; 9159703 |
| UCB SA | 4719 | &nbsp;&nbsp; 1421820 |
| WaVe Life Sciences Ltd.<sup>(a)</sup> | 30090 | &nbsp;&nbsp; 218153 |
|  |  | &nbsp;&nbsp; 192913133 |
| **Total Common Stocks — 97.2%** <br>**(Cost: $336,974,316)** | **Total Common Stocks — 97.2%** <br>**(Cost: $336,974,316)** | &nbsp;&nbsp; 517862362 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
|  | *Benefical* <br>*Interest (000)*<br>|  |
| **Other Interests** | **Other Interests** | **Other Interests** |
| **Biotechnology — 0.0%** | **Biotechnology — 0.0%** |  |
| Affinivax, Inc., (Acquired 08/18/22, Cost: $—)<sup>(c)(e)(f)</sup> | $6 | &nbsp;&nbsp; 23235 |
| **Total Other Interests — 0.0%** <br>**(Cost: $—)** | **Total Other Interests — 0.0%** <br>**(Cost: $—)** | &nbsp;&nbsp; 23235 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
|  | <br>*Shares*<br>|  |
| **Preferred Securities** | **Preferred Securities** | **Preferred Securities** |
| **Preferred Stocks — 0.7%**<sup>(a)(c)(e)</sup> | **Preferred Stocks — 0.7%**<sup>(a)(c)(e)</sup> | **Preferred Stocks — 0.7%**<sup>(a)(c)(e)</sup> |
| **Biotechnology — 0.5%** | **Biotechnology — 0.5%** |  |
| &nbsp;&nbsp;&nbsp; Adarx Pharamaceuticals, Inc., Series C, (Acquired <br> 08/02/23, Cost: $440,003)<br>| 52885 | &nbsp;&nbsp; 693322 |
| &nbsp;&nbsp;&nbsp; Angitia Biopharmaceuticals Ltd., Series D, (Acquired <br> 01/27/26, Cost: $567,428)<br>| 57448 | &nbsp;&nbsp; 568161 |

---

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** |  |
| &nbsp;&nbsp;&nbsp; Cellarity, Inc., Series B, Class B, (Acquired 01/15/21, <br> Cost: $265,002)<br>| 44167 | &nbsp;&nbsp; $107767 |
| &nbsp;&nbsp;&nbsp; Genesis Therapeutics, Inc., Series B, (Acquired <br> 08/10/23, Cost: $292,001)<br>| 57170 | &nbsp;&nbsp; 312720 |
| &nbsp;&nbsp;&nbsp; Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: <br> $175,737)<br>| 168216 | &nbsp;&nbsp; 50465 |
| Kartos Therapeutics, Inc. |  |  |
| &nbsp;&nbsp;&nbsp; (Acquired 02/12/26, Cost: $34,186) | 34186 | &nbsp;&nbsp; 34343 |
| &nbsp;&nbsp;&nbsp; Series C, (Acquired 08/22/23, Cost: $485,124) | 85817 | &nbsp;&nbsp; 487441 |
| &nbsp;&nbsp;&nbsp; Series D, (Acquired 02/19/25, Cost: $133,467) | 23610 | &nbsp;&nbsp; 134105 |
| &nbsp;&nbsp;&nbsp; Laronde, Inc., Series B, (Acquired 07/28/21, Cost: <br> $590,800)<br>| 21100 | &nbsp;&nbsp; 407652 |
|  |  | &nbsp;&nbsp; 2795976 |
| **Health Care Equipment & Supplies — 0.1%** | **Health Care Equipment & Supplies — 0.1%** |  |
| &nbsp;&nbsp;&nbsp; EXO Imaging, Inc., Series D, (Acquired 07/24/24, Cost: <br> $28,863)<br>| 47496 | &nbsp;&nbsp; 35147 |
| &nbsp;&nbsp;&nbsp; Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: <br> $1,070,001)<br>| 367395 | &nbsp;&nbsp; 242481 |
| &nbsp;&nbsp;&nbsp; Quanta Dialysis Technologies Ltd., Series D, (Acquired <br> 06/18/21, Cost: $515,759)<br>| 4243029 | &nbsp;&nbsp; 202179 |
| &nbsp;&nbsp;&nbsp; Swift Health Systems, Inc., Series D, (Acquired 08/27/21, <br> Cost: $286,998)<br>| 93 | &nbsp;&nbsp; 206 |
|  |  | &nbsp;&nbsp; 480013 |
| **Pharmaceuticals — 0.1%** | **Pharmaceuticals — 0.1%** |  |
| &nbsp;&nbsp;&nbsp; Insitro, Inc., Series C, (Acquired 03/10/21, Cost: <br> $560,000)<br>| 30616 | &nbsp;&nbsp; 255950 |
|  |  | &nbsp;&nbsp; 3531939 |
| **Total Preferred Securities — 0.7%** <br>**(Cost: $5,445,369)** | **Total Preferred Securities — 0.7%** <br>**(Cost: $5,445,369)** | &nbsp;&nbsp; 3531939 |
| **Rights** | **Rights** | **Rights** |
| **Biotechnology**<sup>(e)</sup> **— 0.0%** | **Biotechnology**<sup>(e)</sup> **— 0.0%** |  |
| Blueprint Medicines Corp., CVR | 15552 | &nbsp;&nbsp; 15552 |
| Korro Bio, Inc., CVR | 28060 | &nbsp;&nbsp; — |
| Mirati Therapeutics, Inc. CVR | 15747 | &nbsp;&nbsp; 12440 |
|  |  | &nbsp;&nbsp; 27992 |
| **Health Care Equipment & Supplies — 0.0%** | **Health Care Equipment & Supplies — 0.0%** |  |
| Abiomed, Inc., CVR<sup>(e)</sup> | 14359 | &nbsp;&nbsp; 33313 |
| **Total Rights — 0.0%** <br>**(Cost: $32,823)** | **Total Rights — 0.0%** <br>**(Cost: $32,823)** | &nbsp;&nbsp; 61305 |
| **Warrants** | **Warrants** | **Warrants** |
| **Biotechnology — 0.0%** | **Biotechnology — 0.0%** |  |
| &nbsp;&nbsp;&nbsp; Goldfinch Ltd., (Issued/Exercisable 02/10/26, 1 Share for <br> 1 Warrant, Expires 11/20/35, Strike Price USD <br> 1.18)<sup>(a)(e)</sup><br>| 21784 | &nbsp;&nbsp; — |
| **Total Warrants — 0.0%** <br>**(Cost: $22,758)** | **Total Warrants — 0.0%** <br>**(Cost: $22,758)** | &nbsp;&nbsp; — |
| **Total Long-Term Investments — 97.9%** <br>**(Cost: $342,475,266)** | **Total Long-Term Investments — 97.9%** <br>**(Cost: $342,475,266)** | &nbsp;&nbsp; 521478841 |

---

Schedule of Investments

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Trust (BME)** 

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 3.7%** | **Money Market Funds — 3.7%** |  |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency Shares, <br> 3.77%<sup>(g)(h)(i)</sup><br>| 4183703 | &nbsp;&nbsp; $4184540 |
| &nbsp;&nbsp;&nbsp; BlackRock Liquidity Funds, T-Fund, Institutional Shares, <br> 3.55%<sup>(g)(h)</sup><br>| 15410175 | &nbsp;&nbsp; 15410175 |
| **Total Short-Term Securities — 3.7%** <br>**(Cost: $19,594,715)** | **Total Short-Term Securities — 3.7%** <br>**(Cost: $19,594,715)** | &nbsp;&nbsp; 19594715 |
| **Total Investments — 101.6%** <br>**(Cost: $362,069,981)** | **Total Investments — 101.6%** <br>**(Cost: $362,069,981)** | &nbsp;&nbsp; 541073556 |
| **Liabilities in Excess of Other Assets — (1.6)%** | **Liabilities in Excess of Other Assets — (1.6)%** | &nbsp;&nbsp; (8441003)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | &nbsp;&nbsp; $532632553 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. 

<sup>(c)</sup> Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,357,513, representing 0.8% of its net assets as of period end, and an original cost of $6,912,368. 

<sup>(d)</sup> All or a portion of this security is on loan.

<sup>(e)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(f)</sup> Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities. 

<sup>(g)</sup> Affiliate of the Trust.

<sup>(h)</sup> Annualized 7-day yield as of period end.

<sup>(i)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2026 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*12/31/25*<br>| *Proceeds* <br>*from Sales*<br>| *Net* <br>*Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*03/31/26*<br>| *Shares* <br>*Held at* <br>*03/31/26*<br>| *Income* | *Capital Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| BlackRock Cash Funds: Institutional, SL Agency Shares | $893600<br> $3291211 <br><sup>(a)</sup><br>| &nbsp;&nbsp; $— | $(271)<br>| $— | $4184540 | 4183703 | $3193 <br><sup>(b)</sup><br>| &nbsp;&nbsp; $— |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares | 4021533<br> 11388642 <br><sup>(a)</sup><br>| &nbsp;&nbsp; — |  |  | 15410175 | 15410175 | 85210 | &nbsp;&nbsp; — |
|  |  |  | $(271)<br>| $— | $19594715 |  | $88403 | &nbsp;&nbsp; $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

**Fair Value Hierarchy as of Period End**

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 – Unadjusted price quotations in active markets/exchanges that the Trust has the ability to access for identical assets or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of financial instruments, refer to its most recent financial statements.

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Trust (BME)** 

**Fair Value Hierarchy as of Period End (continued)**

The following table summarizes the Trust's financial instruments categorized in the fair value hierarchy. The breakdown of the Trust's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biotechnology | &nbsp;&nbsp; $165139752 | &nbsp;&nbsp;&nbsp;&nbsp; $474158 | &nbsp;&nbsp;&nbsp;&nbsp; $504000 | &nbsp;&nbsp;&nbsp;&nbsp; $166117910 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Health Care Equipment & Supplies | &nbsp;&nbsp; 80109208 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 158880 | &nbsp;&nbsp;&nbsp;&nbsp; 80268088 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Health Care Providers & Services | &nbsp;&nbsp; 40374350 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 40374350 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Health Care Technology | &nbsp;&nbsp; 1528593 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 1528593 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life Sciences Tools & Services | &nbsp;&nbsp; 36660288 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 36660288 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmaceuticals | &nbsp;&nbsp; 180523835 | &nbsp;&nbsp;&nbsp;&nbsp; 12389298 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 192913133 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Interests | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 23235 | &nbsp;&nbsp;&nbsp;&nbsp; 23235 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Securities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Stocks | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 3531939 | &nbsp;&nbsp;&nbsp;&nbsp; 3531939 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rights | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 61305 | &nbsp;&nbsp;&nbsp;&nbsp; 61305 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warrants | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 19594715 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 19594715 |
|  | &nbsp;&nbsp; $523930741 | &nbsp;&nbsp;&nbsp;&nbsp; $12863456 | &nbsp;&nbsp;&nbsp;&nbsp; $4279359 | &nbsp;&nbsp;&nbsp;&nbsp; $541073556 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation**  | **Portfolio Abbreviation**  |
| ADR | American Depositary Receipt |
| CVR | Contingent Value Right |

---

Schedule of Investments

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** BlackRock Health Sciences Trust

- **b. Investment Company Act file number:** 811-21702

- **c. CIK number of Registrant:** 0001314966

- **d. LEI of Registrant:** 4UL0KI4EPYFKMUU31I34

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 BELLEVUE PARKWAY

  - **City:** WILMINGTON

  - **State:** DE

  - **Foreign country:** US

  - **Zip / Postal Code:** 19809

  - **Telephone number:** 800-441-7762

**Item A.2. Information about the Series.**

- **a. Name of Series:** BlackRock Health Sciences Trust

- **c. LEI of Series:** 4UL0KI4EPYFKMUU31I34

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-12-31

- **b. Date as of which information is reported:** 2026-03-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $536656639.79

**Total Liabilities:** $4097736.97

**Net Assets:** $532558902.82

**Cash Not Reported:** $521.82

**Monthly Return Information**

| Class        | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID N/A | 0.14%                | 2.31%                | -6.78%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $5365686.77              | $-4674755.87                               |
| Month 2  | $280785.70               | $12469506.29                               |
| Month 3  | $8247456.08              | $-47681250.79                              |

**Designated Index Information**

- **Index Name:** MSCI USA IMI Health Care Call Overwrite Index

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                                         | Title                                                   | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Abbott Laboratories                          | Abbott Laboratories                                     | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |    119561 | NS      | $12275327.87  | 2.30%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                                   | AbbVie Inc                                              | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    100720 | NS      | $21905592.80  | 4.11%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA ABIOMED INC                           | CONTRA ABIOMED INC                                      | CUSIP: 003CVR016<br>LEI: N/A                  | Long             |  | CORP              | US        |     14359 | NS      | $33312.88     | 0.01%             |  |  |  | No            |                  3 | On Loan: No      |
| Agilent Technologies Inc                     | Agilent Technologies Inc                                | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |     23884 | NS      | $2722298.32   | 0.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Agios Pharmaceuticals Inc                    | Agios Pharmaceuticals Inc                               | CUSIP: 00847X104<br>LEI: 529900ONJHY8EOGYT555 | Long             | EC               | CORP              | US        |     30245 | NS      | $1023188.35   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Aktis Oncology Inc                           | Aktis Oncology Inc                                      | CUSIP: 01021M104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     23229 | NS      | $415566.81    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Allogene Therapeutics Inc                    | Allogene Therapeutics Inc                               | CUSIP: 019770106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    105465 | NS      | $257334.60    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                  | Alnylam Pharmaceuticals Inc                             | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |      8378 | NS      | $2772028.86   | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Alumis Inc                                   | Alumis Inc                                              | CUSIP: 022307102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     25795 | NS      | $568263.85    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Cencora Inc                                  | Cencora Inc                                             | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |     15981 | NS      | $5020271.34   | 0.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                    | Amgen Inc                                               | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |     51861 | NS      | $18247292.85  | 3.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Elevance Health Inc                          | Elevance Health Inc                                     | CUSIP: 036752103<br>LEI: 8MYN82XMYQH89CTMTH67 | Long             | EC               | CORP              | US        |      7713 | NS      | $2257980.75   | 0.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc                      | Apogee Therapeutics Inc                                 | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     17780 | NS      | $1496542.60   | 0.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                                  | Arcellx Inc                                             | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      8208 | NS      | $942442.56    | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc                        | Arcus Biosciences Inc                                   | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     39654 | NS      | $856526.40    | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                    | Argenx SE                                               | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     10637 | NS      | $7767669.25   | 1.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Autolus Therapeutics PLC                     | Autolus Therapeutics PLC                                | CUSIP: 05280R100<br>LEI: 549300C0KZP8EYROLL02 | Long             | EC               | CORP              | GB        |     23620 | NS      | $32595.60     | 0.01%             |  |  |  | No            |                  1 | On Loan: —       |
| Bicara Therapeutics Inc                      | Bicara Therapeutics Inc                                 | CUSIP: 055477103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14144 | NS      | $281324.16    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Beam Therapeutics Inc                        | Beam Therapeutics Inc                                   | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     14611 | NS      | $348180.13    | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| BioMarin Pharmaceutical Inc                  | BioMarin Pharmaceutical Inc                             | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |     29577 | NS      | $1670804.73   | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                   | Biogen Inc                                              | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |     31869 | NS      | $5842543.77   | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                              | Bio-Techne Corp                                         | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |     17090 | NS      | $893123.40    | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                  | BioNTech SE                                             | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |      3695 | NS      | $328411.60    | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA BLUEPRINT MEDIC                       | CONTRA BLUEPRINT MEDIC                                  | CUSIP: 096CVR048<br>LEI: 5299004CC60O9T5HVM83 | Long             |  | CORP              | US        |     15552 | NS      | $15552.00     | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| AstraZeneca PLC                              | AstraZeneca PLC                                         | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     33842 | NS      | $6617462.88   | 1.24%             |  |  |  | No            |                  2 | On Loan: No      |
| Boston Scientific Corp                       | Boston Scientific Corp                                  | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    132943 | NS      | $8342173.25   | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| BridgeBio Oncology Therapeutics Inc          | BridgeBio Oncology Therapeutics Inc                     | CUSIP: 107924102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     60030 | NS      | $537268.50    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc                         | Bridgebio Pharma Inc                                    | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |     18055 | NS      | $1340764.30   | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Bright Minds Biosciences Inc                 | Bright Minds Biosciences Inc                            | CUSIP: 10919W405<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |      8368 | NS      | $610612.96    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co                      | Bristol-Myers Squibb Co                                 | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |     96259 | NS      | $5838108.35   | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Bruker Corp                                  | Bruker Corp                                             | CUSIP: 116794108<br>LEI: LEBZ6VLQ6I8XB1NHVY15 | Long             | EC               | CORP              | US        |     43307 | NS      | $1564248.84   | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| CVS Health Corp                              | CVS Health Corp                                         | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |     31771 | NS      | $2281793.22   | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| CG oncology Inc                              | CG oncology Inc                                         | CUSIP: 156944100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      5095 | NS      | $344829.60    | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Charles River Laboratories International Inc | Charles River Laboratories International Inc            | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |      4936 | NS      | $851460.00    | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Cogent Biosciences Inc                       | Cogent Biosciences Inc                                  | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     72020 | NS      | $2772049.80   | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Cooper Cos Inc/The                           | Cooper Cos Inc/The                                      | CUSIP: 216648501<br>LEI: QJKMVPIGLH7530PCUE20 | Long             | EC               | CORP              | US        |     26747 | NS      | $1912410.50   | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Corvus Pharmaceuticals Inc                   | Corvus Pharmaceuticals Inc                              | CUSIP: 221015100<br>LEI: 549300I3AVJ8F75NCX65 | Long             | EC               | CORP              | US        |      9689 | NS      | $141750.07    | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc                             | Cytokinetics Inc                                        | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     16255 | NS      | $1071367.05   | 0.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                 | Danaher Corp                                            | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |     54385 | NS      | $10311396.00  | 1.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Denali Therapeutics Inc                      | Denali Therapeutics Inc                                 | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |     22218 | NS      | $426585.60    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                   | Dexcom Inc                                              | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |     57910 | NS      | $3636748.00   | 0.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics Inc                    | Dianthus Therapeutics Inc                               | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |     16460 | NS      | $1381323.20   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc                        | Dyne Therapeutics Inc                                   | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     23908 | NS      | $433452.04    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Edgewise Therapeutics Inc                    | Edgewise Therapeutics Inc                               | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     22279 | NS      | $701788.50    | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Edwards Lifesciences Corp                    | Edwards Lifesciences Corp                               | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    149905 | NS      | $12004392.40  | 2.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Eikon Therapeutics Inc                       | Eikon Therapeutics Inc                                  | CUSIP: 282564103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     63218 | NS      | $668846.44    | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Elanco Animal Health Inc                     | Elanco Animal Health Inc                                | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |     41073 | NS      | $982876.89    | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Enanta Pharmaceuticals Inc                   | Enanta Pharmaceuticals Inc                              | CUSIP: 29251M106<br>LEI: 529900SSN4DODDQSN594 | Long             | EC               | CORP              | US        |     42512 | NS      | $536926.56    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Erasca Inc                                   | Erasca Inc                                              | CUSIP: 29479A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     62282 | NS      | $1007722.76   | 0.19%             |  |  |  | No            |                  1 | On Loan: No      |
| Exelixis Inc                                 | Exelixis Inc                                            | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |     19863 | NS      | $851924.07    | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| EyePoint Inc                                 | EyePoint Inc                                            | CUSIP: 30233G209<br>LEI: 549300QE1RU34T50MR69 | Long             | EC               | CORP              | US        |     16320 | NS      | $210364.80    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| 4D Molecular Therapeutics Inc                | 4D Molecular Therapeutics Inc                           | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     11491 | NS      | $106981.21    | 0.02%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA FREQUENCY THERA                       | CONTRA FREQUENCY THERA                                  | CUSIP: 358CVR025<br>LEI: N/A                  | Long             |  | CORP              | US        |     28060 | NS      | $0.28         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Gilead Sciences Inc                          | Gilead Sciences Inc                                     | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    150487 | NS      | $20973373.19  | 3.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Glaukos Corp                                 | Glaukos Corp                                            | CUSIP: 377322102<br>LEI: 5299004JA1LHE21M6T14 | Long             | EC               | CORP              | US        |      7625 | NS      | $820907.50    | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Gossamer Bio Inc                             | Gossamer Bio Inc                                        | CUSIP: 38341P102<br>LEI: 549300ZOC0N2W6PSFR58 | Long             | EC               | CORP              | US        |     31955 | NS      | $10497.22     | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                          | Guardant Health Inc                                     | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |     39876 | NS      | $3683346.12   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| HCA Healthcare Inc                           | HCA Healthcare Inc                                      | CUSIP: 40412C101<br>LEI: 529900PH4ZGUH2MNEU89 | Long             | EC               | CORP              | US        |     10937 | NS      | $5175825.88   | 0.97%             |  |  |  | No            |                  1 | On Loan: No      |
| Hologic Inc                                  | Hologic Inc                                             | CUSIP: 436440101<br>LEI: 549300DYP6F5ZJL0LB74 | Long             | EC               | CORP              | US        |     12193 | NS      | $921668.87    | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Humana Inc                                   | Humana Inc                                              | CUSIP: 444859102<br>LEI: 529900YLDW34GJAO4J06 | Long             | EC               | CORP              | US        |      6765 | NS      | $1172983.35   | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| IDEXX Laboratories Inc                       | IDEXX Laboratories Inc                                  | CUSIP: 45168D104<br>LEI: OGMTXK0LUU1HKV2P0J84 | Long             | EC               | CORP              | US        |      6712 | NS      | $3771405.68   | 0.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                                 | Illumina Inc                                            | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |     13293 | NS      | $1638495.18   | 0.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunome Inc                                 | Immunome Inc                                            | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     25340 | NS      | $554185.80    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC                      | Immunocore Holdings PLC                                 | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |     16565 | NS      | $499434.75    | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                  | Incyte Corp                                             | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |     34568 | NS      | $3253540.16   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                   | Insmed Inc                                              | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     34614 | NS      | $5660081.28   | 1.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc                    | Intellia Therapeutics Inc                               | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |     45705 | NS      | $585938.10    | 0.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Intuitive Surgical Inc                       | Intuitive Surgical Inc                                  | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |     27505 | NS      | $12679529.95  | 2.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc                    | Ionis Pharmaceuticals Inc                               | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     14983 | NS      | $1125073.47   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                           | IQVIA Holdings Inc                                      | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |     12502 | NS      | $2132091.08   | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                            | Johnson & Johnson                                       | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    234293 | NS      | $57270580.92  | 10.75%            |  |  |  | No            |                  1 | On Loan: No      |
| KalVista Pharmaceuticals Inc                 | KalVista Pharmaceuticals Inc                            | CUSIP: 483497103<br>LEI: 529900Q7IDA3WUGRZA51 | Long             | EC               | CORP              | US        |     18705 | NS      | $376531.65    | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Kodiak Sciences Inc                          | Kodiak Sciences Inc                                     | CUSIP: 50015M109<br>LEI: 254900IXI5NI8C9OQE24 | Long             | EC               | CORP              | US        |     14972 | NS      | $570732.64    | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Kymera Therapeutics Inc                      | Kymera Therapeutics Inc                                 | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      4712 | NS      | $392462.48    | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| LB Pharmaceuticals Inc                       | LB Pharmaceuticals Inc                                  | CUSIP: 50180M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     48308 | NS      | $1191275.28   | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                               | Eli Lilly & Co                                          | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |     59379 | NS      | $54615022.83  | 10.26%            |  |  |  | No            |                  1 | On Loan: No      |
| MBX Biosciences Inc                          | MBX Biosciences Inc                                     | CUSIP: 55287L101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     28457 | NS      | $849441.45    | 0.16%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                       | UCB SA                                                  | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |      4719 | NS      | $1421819.57   | 0.27%             |  |  |  | No            |                  2 | On Loan: No      |
| Maze Therapeutics Inc                        | Maze Therapeutics Inc                                   | CUSIP: 578784100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     15965 | NS      | $476555.25    | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |
| McKesson Corp                                | McKesson Corp                                           | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |      2993 | NS      | $2590022.48   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Medline Inc                                  | Medline Inc                                             | CUSIP: 58507V107<br>LEI: 984500FAN6J1P8566D43 | Long             | EC               | CORP              | US        |     70645 | NS      | $3143702.50   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                               | Merck & Co Inc                                          | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    237354 | NS      | $28551312.66  | 5.36%             |  |  |  | No            |                  1 | On Loan: No      |
| Mettler-Toledo International Inc             | Mettler-Toledo International Inc                        | CUSIP: 592688105<br>LEI: 5493000BD5GJNUDIUG10 | Long             | EC               | CORP              | US        |       395 | NS      | $498174.00    | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA MIRATI THERAPEU                       | CONTRA MIRATI THERAPEU                                  | CUSIP: 604CVR027<br>LEI: 529900GYRW59IDQV6N54 | Long             |  | CORP              | US        |     15747 | NS      | $12440.13     | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Moderna Inc                                  | Moderna Inc                                             | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |     48852 | NS      | $2481681.60   | 0.47%             |  |  |  | No            |                  1 | On Loan: No      |
| Monte Rosa Therapeutics Inc                  | Monte Rosa Therapeutics Inc                             | CUSIP: 61225M102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     27954 | NS      | $459843.30    | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| MoonLake Immunotherapeutics                  | MoonLake Immunotherapeutics                             | CUSIP: 61559X104<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |      5908 | NS      | $110125.12    | 0.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera Inc                                   | Natera Inc                                              | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     11821 | NS      | $2364081.79   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                   | Neurocrine Biosciences Inc                              | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |      6793 | NS      | $894909.82    | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                                  | Novartis AG                                             | CUSIP: 66987V109<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |     21810 | NS      | $3331477.50   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvalent Inc                                 | Nuvalent Inc                                            | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     28618 | NS      | $2931914.10   | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| Ocular Therapeutix Inc                       | Ocular Therapeutix Inc                                  | CUSIP: 67576A100<br>LEI: 529900ABAWFXOHSIHG03 | Long             | EC               | CORP              | US        |     22645 | NS      | $191803.15    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Orchestra BioMed Holdings Inc                | Orchestra BioMed Holdings Inc                           | CUSIP: 68572M106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     17635 | NS      | $74948.75     | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| Oruka Therapeutics Inc                       | Oruka Therapeutics Inc                                  | CUSIP: 687604108<br>LEI: 529900TG7O4ESUDMGI54 | Long             | EC               | CORP              | US        |     15986 | NS      | $784113.30    | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc                         | PTC Therapeutics Inc                                    | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |      4329 | NS      | $294934.77    | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Palvella Therapeutics Inc                    | Palvella Therapeutics Inc                               | CUSIP: 697947109<br>LEI: 254900AJDH8PAOOI5T33 | Long             | EC               | CORP              | US        |      4480 | NS      | $558432.00    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Penumbra Inc                                 | Penumbra Inc                                            | CUSIP: 70975L107<br>LEI: 549300RGE06P3ECANU72 | Long             | EC               | CORP              | US        |     11606 | NS      | $3811062.22   | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                                   | Pfizer Inc                                              | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |    522250 | NS      | $14664780.00  | 2.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Protagonist Therapeutics Inc                 | Protagonist Therapeutics Inc                            | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     32058 | NS      | $3378913.20   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| Quest Diagnostics Inc                        | Quest Diagnostics Inc                                   | CUSIP: 74834L100<br>LEI: 8MCWUBXQ0WE04KMXBX50 | Long             | EC               | CORP              | US        |      7463 | NS      | $1462598.74   | 0.27%             |  |  |  | No            |                  1 | On Loan: No      |
| RadNet Inc                                   | RadNet Inc                                              | CUSIP: 750491102<br>LEI: 529900RECG94V2IZJ970 | Long             | EC               | CORP              | US        |      9485 | NS      | $530116.65    | 0.10%             |  |  |  | No            |                  1 | On Loan: —       |
| Regeneron Pharmaceuticals Inc                | Regeneron Pharmaceuticals Inc                           | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |      7712 | NS      | $5958599.68   | 1.12%             |  |  |  | No            |                  1 | On Loan: No      |
| REGENXBIO Inc                                | REGENXBIO Inc                                           | CUSIP: 75901B107<br>LEI: 549300EOES47LATSET33 | Long             | EC               | CORP              | US        |     18415 | NS      | $154317.70    | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                     | Revolution Medicines Inc                                | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     26560 | NS      | $2582960.00   | 0.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                   | Rhythm Pharmaceuticals Inc                              | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |     46799 | NS      | $4070109.03   | 0.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Scholar Rock Holding Corp                    | Scholar Rock Holding Corp                               | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |     19764 | NS      | $971598.24    | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Stoke Therapeutics Inc                       | Stoke Therapeutics Inc                                  | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |     41095 | NS      | $1338053.20   | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Stryker Corp                                 | Stryker Corp                                            | CUSIP: 863667101<br>LEI: 5493002F0SC4JTBU5137 | Long             | EC               | CORP              | US        |     23649 | NS      | $7770824.91   | 1.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc                      | Summit Therapeutics Inc                                 | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     80150 | NS      | $1519644.00   | 0.29%             |  |  |  | No            |                  1 | On Loan: —       |
| Syndax Pharmaceuticals Inc                   | Syndax Pharmaceuticals Inc                              | CUSIP: 87164F105<br>LEI: 529900OF94TRHKZVBS87 | Long             | EC               | CORP              | US        |      5165 | NS      | $120654.40    | 0.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Terns Pharmaceuticals Inc                    | Terns Pharmaceuticals Inc                               | CUSIP: 880881107<br>LEI: 254900S1ZDQMF4MYP709 | Long             | EC               | CORP              | US        |     32290 | NS      | $1702328.80   | 0.32%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd           | Teva Pharmaceutical Industries Ltd                      | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |    304107 | NS      | $9159702.84   | 1.72%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc                 | Thermo Fisher Scientific Inc                            | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |     19123 | NS      | $9399528.19   | 1.76%             |  |  |  | No            |                  1 | On Loan: No      |
| TScan Therapeutics Inc                       | TScan Therapeutics Inc                                  | CUSIP: 89854M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     48273 | NS      | $48755.73     | 0.01%             |  |  |  | No            |                  1 | On Loan: No      |
| ADARX PHARMACEUTICALS INC                    | ADARX PHARMACEUTICALS INC                               | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     52885 | NS      | $693322.35    | 0.13%             |  |  |  | Yes           |                  3 | On Loan: No      |
| GENESIS THERAPEUTICS INC                     | GENESIS THERAPEUTICS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     57170 | NS      | $312719.90    | 0.06%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |     85817 | NS      | $487440.56    | 0.09%             |  |  |  | Yes           |                  3 | On Loan: No      |
| United Therapeutics Corp                     | United Therapeutics Corp                                | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |      4903 | NS      | $2907380.94   | 0.55%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc                       | UnitedHealth Group Inc                                  | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |     59867 | NS      | $16199411.53  | 3.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Upstream Bio Inc                             | Upstream Bio Inc                                        | CUSIP: 91678A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     30052 | NS      | $270468.00    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Vaxcyte Inc                                  | Vaxcyte Inc                                             | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |      7541 | NS      | $438207.51    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Veeva Systems Inc                            | Veeva Systems Inc                                       | CUSIP: 922475108<br>LEI: 549300YZEXPDB92M2F02 | Long             | EC               | CORP              | US        |      8702 | NS      | $1528593.32   | 0.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                   | Vertex Pharmaceuticals Inc                              | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     31983 | NS      | $14281688.82  | 2.68%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc                      | Viking Therapeutics Inc                                 | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |     36985 | NS      | $1203491.90   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Viridian Therapeutics Inc                    | Viridian Therapeutics Inc                               | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |     45005 | NS      | $880297.80    | 0.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Vor BioPharma Inc                            | Vor BioPharma Inc                                       | CUSIP: 929033207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     10020 | NS      | $178756.80    | 0.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Voyager Therapeutics Inc                     | Voyager Therapeutics Inc                                | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |     31420 | NS      | $121281.20    | 0.02%             |  |  |  | No            |                  1 | On Loan: No      |
| BlackRock Liquidity Funds                    | BlackRock Liquidity Funds: T-Fund, Institutional Shares | CUSIP: 09248U718<br>LEI: 5493007YVNX55LTRQ706 | Long             | STIV             | RF                | US        |  15410175 | NS      | $15410174.94  | 2.89%             |  |  |  | No            |                  1 | On Loan: No      |
| GOLDFINCH BIO INC                            | GOLDFINCH BIO INC                                       | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    168216 | NS      | $50464.80     | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Waters Corp                                  | Waters Corp                                             | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |     10927 | NS      | $3254060.60   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| CELLARITY INC                                | CELLARITY INC                                           | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     44167 | NS      | $107767.48    | 0.02%             |  |  |  | Yes           |                  3 | On Loan: No      |
| INSITRO INC                                  | INSITRO INC                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     30616 | NS      | $255949.76    | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Quanta Dialysis Technologies Ltd             | Quanta Dialysis Technologies Ltd                        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        |   4243029 | NS      | $202178.70    | 0.04%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUCLEIX LTD                                  | NUCLEIX LTD                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |    367395 | NS      | $242480.70    | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| LARONDE INC                                  | LARONDE INC                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     21100 | NS      | $407652.00    | 0.08%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SWIFT HEALTH SYSTEMS INC                     | SWIFT HEALTH SYSTEMS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |        93 | NS      | $206.45       | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| AFFINIVAX INC                                | AFFINIVAX INC                                           | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      6331 | NS      | $23234.77     | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUCLEIX LTD                                  | NUCLEIX LTD                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |       200 | NS      | $158504.00    | 0.03%             |  |  |  | Yes           |                  3 | On Loan: No      |
| West Pharmaceutical Services Inc             | West Pharmaceutical Services Inc                        | CUSIP: 955306105<br>LEI: 5493007NKRGM1RJQ1P16 | Long             | EC               | CORP              | US        |      5328 | NS      | $1335409.92   | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| EXO IMAGING INC                              | EXO IMAGING INC                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     47496 | NS      | $35147.33     | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| EXO IMAGING INC                              | EXO IMAGING INC                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1017 | NS      | $376.44       | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |     23610 | NS      | $134104.80    | 0.03%             |  |  |  | Yes           |                  3 | On Loan: No      |
| BlackRock Funds III                          | BlackRock Cash Funds: Institutional, SL Agency Shares   | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |   1612509 | NS      | $1612831.85   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| BRIDGEBIO ONCOLOGY THERAPEUTICS INC          | BRIDGEBIO ONCOLOGY THERAPEUTICS INC                     | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     15582 | NS      | $139458.90    | 0.03%             |  |  |  | Yes           |                  2 | On Loan: No      |
| KAILERA THERAPEUTICS INC                     | KAILERA THERAPEUTICS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     36000 | NS      | $504000.00    | 0.09%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Angitia Biopharmaceuticals Limited           | Angitia Biopharmaceuticals Limited                      | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |     57448 | NS      | $568160.72    | 0.11%             |  |  |  | Yes           |                  3 | On Loan: No      |
| GOLDFINCH EQUITY WARRANTS                    | GOLDFINCH EQUITY WARRANTS                               | CUSIP: 000000000<br>LEI: N/A                  | N/A              | DE               |  | US        |     21784 | NS      | $0.22         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     34186 | NS      | $34342.81     | 0.01%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Galderma Group AG                            | Galderma Group AG                                       | CUSIP: 000000000<br>LEI: 89450001OK6O8ELQ4584 | Long             | EC               | CORP              | CH        |     16599 | NS      | $3262262.52   | 0.61%             |  |  |  | No            |                  2 | On Loan: No      |
| Daiichi Sankyo Co Ltd                        | Daiichi Sankyo Co Ltd                                   | CUSIP: 000000000<br>LEI: 353800XGIU2IHQGC9504 | Long             | EC               | CORP              | JP        |     60800 | NS      | $1087752.33   | 0.20%             |  |  |  | No            |                  2 | On Loan: No      |
| Zealand Pharma A/S                           | Zealand Pharma A/S                                      | CUSIP: 000000000<br>LEI: 549300ITBB1ULBL4CZ12 | Long             | EC               | CORP              | DK        |      7187 | NS      | $334698.60    | 0.06%             |  |  |  | No            |                  2 | On Loan: No      |
| Nyxoah SA                                    | Nyxoah SA                                               | CUSIP: 000000000<br>LEI: 5493002O1ESKZ18OXR80 | Long             | EC               | CORP              | BE        |     29659 | NS      | $86604.28     | 0.02%             |  |  |  | No            |                  1 | On Loan: —       |
| Biohaven Ltd                                 | Biohaven Ltd                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | VG        |     30469 | NS      | $257767.74    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                                | Medtronic PLC                                           | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |     77050 | NS      | $6676382.50   | 1.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Novocure Ltd                                 | Novocure Ltd                                            | CUSIP: 000000000<br>LEI: 213800YPP55UMHWA4826 | Long             | EC               | CORP              | JE        |     49947 | NS      | $544422.30    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Roivant Sciences Ltd                         | Roivant Sciences Ltd                                    | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | BM        |     41221 | NS      | $1141821.70   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| STERIS PLC                                   | STERIS PLC                                              | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | IE        |      5880 | NS      | $1300244.40   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Alcon AG                                     | Alcon AG                                                | CUSIP: 000000000<br>LEI: 549300LDT5AP8S0NBM78 | Long             | EC               | CORP              | CH        |      5751 | NS      | $433337.85    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| WaVe Life Sciences Ltd                       | WaVe Life Sciences Ltd                                  | CUSIP: 000000000<br>LEI: 54930070006GPKFYZ813 | Long             | EC               | CORP              | SG        |     30090 | NS      | $218152.50    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-04-30

**Name of Applicant:** BlackRock Health Sciences Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer